Lupus & antiphospholipid syndrome
Glucocorticoid-free remission in patients with SLE in the era of biologics: Immune complex disease is likely to benefit from current medications
Authors' conclusion
In the era of biologics, CR off C was achieved in 28.3% of the patient cohort requiring the start or increase of glucocorticoids for disease activity, with a relatively low rate of flares, suggesting that glucocorticoid-free clinical remission is an achievable target in SLE.
Study context
- Population
- Patients with SLE who needed to start or increase GC for disease activity and were followed up for more than 1 year, Japanmean follow-up 5.4 (±2.6) years
- Participants
- 60 patients
- Outcome
- Rate of achievement of clinical remission off corticosteroids (CR off C): no clinical score on the SLEDAI-2K without GC
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
CR off C achieved · 3.6 (±1.2) years after enrolment
Patients achieving CR off C
17
28.3%
Observational data: associations, not effects.
Further findings
Belimumab and anifrolumab use among achievers
- Achievers using belimumab and anifrolumab
- 8 (47.1%)
Baseline predictors of CR off C
- Male sex, recent enrolment, high GC dose and immune complex (IC) detection significantly predicted CR off C
- Lupus nephritis (LN) and low C3 level tended to predict CR off C
- Multivariate analysis: IC detection was the only predictor of CR off C
Clinical flares after CR off C · median 1.2 years after achievement of CR off C
- Clinical flares among achievers
- 5.9%
Original publication
Glucocorticoid-free remission in patients with SLE in the era of biologics: Immune complex disease is likely to benefit from current medications. Lupus. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →